Genmab — Oktober 2023
-
Selv ikke et overraskende stort fald i den europæiske inflation og et pænt grønt marked kan ændre ved Genmabs performance. Man må bare erkende, at aktien er i bad standing. Som Klarussen er inde på, er man nok afventende ift. diverse data. Havde godt nok ikke regnet med at se den under 2000 igen. Men nå op på hesten. Så længe vi når 3500 i 2024 er jeg tilfreds:-)
-
JNJ putter yderligere $1 bn i kassen https://finance.yahoo.com/news/1-gsk-pay-1-bln-123009978.html
-
Må indrømme, at Genmab er ved at være en udfordring i min portefølje i år. GEN er nede med mere end 30% i år. Jeg håber, i den grad, at næste uges rapportering kan give, bare lidt håb.
-
Selv ikke DSV, der har fået læstelige stryg på det seneste, kan ÅTD bare nærme sig GEN i dårlihdom:-(
-
Der er intet der kan holde aktien ovenvande....Der er nok af undskyldninger/forklaringer. Men egentlig ikke nogen der giver overordnet mening. Når NBI falder, hedder det sig selvfølgelig falder med. Når NBI stiger og Genmab der falder. Så hedder det sig at det er nuværende renteniveaullll Og når vi ikke kan slå på ovenstående, som værende katalysatorer for faldet. Så hedder det sig at det er voldgiftsagen....
-
SITC Abstract 813- Combination of HexaBody-CD27 with PD-(L)1 blockade potentiates single-agent activity leading to enhanced human T-cell effector functions in vitro https://jitc.bmj.com/content/11/Suppl_1/912
-
SITC23 Abstract 1181- GEN1042-mIgG2a, an Fc-inert mouse-human chimeric variant of GEN1042 (DuoBody
-CD40x4-1BB), exhibits in vivo antitumor activity and peripheral immune modulation https://jitc.bmj.com/content/11/Suppl_1/1302 -
SITC23
681- innovaTV 207 Parts E and F: A phase 2 study of tisotumab vedotin in patients with head and neck squamous cell carcinoma (trial in progress) https://jitc.bmj.com/content/11/Suppl_1/772 -
Tepezza sales not yet included in the Amgen sales, but discussed in the call Q3 '23 -In the third quarter, sales of Tepezza reached $453 million, the company said on Tuesday. While Amgen was quick to point out that it was a 2% increase from the previous quarter, it also was an 8% decline year over year. Amgen has a plan to get Tepezza’s groove back, using a playbook that the company employed with vasculitis drug Tavneos after its 2020 acquisition of Chemocentryx.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind